Recognizing and Addressing Rheumatic irAEs from Cancer Immunotherapies

0 Views
Published
Guest: Laura Cappelli, MD, MHS,MS




Patients who are receiving immunotherapy for cancer sometimes develop significant autoimmune complications, which can be fatal. Join Dr. Laura Cappelli, Associate Professor of Medicine and Oncology at the Johns Hopkins University School of Medicine, as she explains how multidisciplinary collaboration can help manage these rheumatic immune-related adverse events (irAEs). Dr. Cappelli also spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.
Category
Oncology
Be the first to comment